The Changing Face of Chromatography

From cutting-edge gene therapies to groundbreaking MRNA vaccines, innovative approaches hold tremendous promise for treating and preventing diseases. However, their development and production pose unique challenges that demand equally innovative solutions. Let’s look at how chromatography, a foundational technique in biopharmaceutical manufacturing, is keeping pace with these new therapies and explore the latest developments in the chromatography market.

- Ayesha Siddiqui

The global chromatography market was worth $11.19 billion in 2021, and is projected to reach $15.33 billion by 2030, as per SkyQuest Technology Consulting. Increased investment in Research and Development (R&D), rise of new therapies, etc. all driving the growth of chromatography market.

Increased investment: Increased investment in R&D activities within the pharmaceutical and biotechnology sectors has resulted in a significant uptick in the utilisation of chromatographic techniques for downstream testing, contributing substantially to market expansion.

Rise of new therapies: Emerging therapies like cell and gene therapies, mRNA, biosimilars, proteomics, genomics, and monoclonal antibodies (mAb) are all advancing innovation in chromatography. Leading players in the field are introducing specific solutions for these therapies. In August 2023, Waters launched XBridge Premier GTx BEH size exclusion chromatography (SEC) columns to enhance gene therapy analysis, particularly for adeno-associated viral (AAV) vectors. Similarly, in 2021 Cytiva introduced HiScreen Fibro PrismA, a new tool for early monoclonal antibody purification process development, complementing their HiTrap Fibro PrismA platform designed for research applications.